etoricoxib / Generic mfg. - LARVOL DELTA

Effectiveness and priority of irradiation and six NSAIDs in prevention heterotopic ossification after total hip arthroplasty: a network meta-analysis of randomized controlled studies. (PubMed, Front Pharmacol) - "The meta-analysis incorporated data from 3,014 patients: 629 administered ibuprofen, 54 with naproxen, 117 receiving celecoxib, 426 on indomethacin, 295 treated with diclofenac, 45 on etoricoxib, 522 subjected to irradiation, and 926 serving as controls. Given the advantages shown by etoricoxib and celecoxib, further randomized controlled trials are recommended to clarify their effects. Our conclusions require confirmation through additional high-quality studies."

Journal • Retrospective data • Orthopedics

Efficacy and safety of genakumab for first-line treatment of gout flare: A phase 2, multicenter, open-label, active controlled, randomized non-inferiority trial (EULAR 2025) - P2 | "Compared with daily oral etoricoxib, a single 200 mg subcutaneous injection of genakumab provides faster, more sustained relief of joint pain over 12 weeks, reduces recurrence risk, and is well tolerated as a first-line treatment for gout flares."

Clinical • Head-to-Head • P2 data • Dyslipidemia • Gout • Hypertriglyceridemia • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology • IL1B

Arcoxia - cause of erythema fixed drug (EAACI 2025) - No abstract available

Immunology

Etoricoxib-Induced DRESS Syndrome (EAACI 2025) - No abstract available

Immunology

Inhibition of Cyclooxygenase-2 Upregulates the Nuclear Factor Erythroid 2-related Factor 2 Signaling Pathway to Mitigate Hepatocyte Ferroptosis in Chronic Liver Injury. (PubMed, J Clin Transl Hepatol) - "In vitro, primary mouse hepatocytes were isolated and treated with dimethyl sulfoxide (DMSO), erastin+DMSO, etoricoxib+erastin+DMSO, and tBHQ+erastin+DMSO. Ferroptosis contributes to the progression of chronic liver injury. Inhibition of COX-2 upregulates Nrf2, mitigating hepatocyte ferroptosis in chronic liver injury."

Journal • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • GPX4

The Effects of Non-Steroidal Anti-Inflammatory Drugs Used for Orthodontic Pain Management on Tooth Movement: A Comprehensive Review of the Literature. (PubMed, J Clin Med) - "Evidence shows that NSAIDs such as aspirin, ketorolac, diclofenac, and nimesulide significantly reduce OTM. The results for ibuprofen, meloxicam, and celecoxib were inconsistent with both no influence or a reduction in OTM, depending on dosage, mode, and duration of administration. Conversely, tenoxicam, nabumetone, etoricoxib, and parecoxib appear to have no effect on OTM. Among these, etoricoxib appears particularly promising due to its favorable gastrointestinal profile, high COX-2 selectivity, and negligible influence on OTM in clinical doses. However, the limited number of human trials highlights the need for further research to develop evidence-based guidelines for pain management that preserve treatment efficiency in orthodontics."

Journal • Review • Pain

Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB) (clinicaltrials.gov) - P=N/A | N=360 | Not yet recruiting | Sponsor: Peking University Third Hospital

New trial • Back Pain • CNS Disorders • Fibromyalgia • Lumbar Back Pain • Mental Retardation • Musculoskeletal Pain • Neuralgia • Pain • Psychiatry • Rheumatology • Sleep Disorder

LIVER SINOSOIDAL ENDOTHELIAL CELL CONTRIBUTES TO LEUKOCYTE RECRUITMENT IN LIVER FIBROSIS THROUGH A CYCLOOXYGENASE-2-DEPENDENT MECHANISM (DDW 2025) - "COX-2 expression in LSECs is up-regulated in liver fibrosis. Upon inflammatory stimulation, COX-2-PGE2-EP2 axis increases chemokines and adhesion molecules through the synergistic activation of NF-κB signaling pathway, leading to leukocyte recruitment and hepatic inflammation. Inhibition of COX-2 by Celecoxib or Etoricoxib attenuate fibrosis and liver injury."

Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • CCL2 • CXCL1 • ICAM1 • LYVE1 • PACERR • PTGS2 • TNFA • VCAM1

Assessing the efficacy and safety of different nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis: A systematic review and network meta-analysis based on RCT trials. (PubMed, PLoS One) - "Compared to other NSAIDs, Etoricoxib, Tiaprofenic, Naproxen, and Diclofenac play a more effective role in improving clinical symptoms of OA; in terms of reducing the incidence of adverse events, Ketoprofen has a lower chance of adverse events. However, the possibility of these results still needs further clinical and basic research for verification."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Immunology • Osteoarthritis • Pain • Rheumatology

Insights into nanostructured lipid carriers of etoricoxib for mitigating radiation-induced lung inflammation and exploring anti-inflammatory mechanisms in rats. (PubMed, Fundam Clin Pharmacol) - "Based on these results, NLCs are one of the most promising ways to deliver anti-inflammatory drugs for treating lung damage caused by radiation."

IO biomarker • Journal • Preclinical • Inflammation • Oncology • Pneumonia • Respiratory Diseases • BAX • BCL2 • CASP3 • CASP8 • CAT • IL6 • TNFA

Pre-emptive Montelukast and Its Effect on Clinical Outcomes After Mandibular Third Molar Surgery: A Triple-blinded Randomized Controlled Trial. (PubMed, J Oral Maxillofac Surg) - "In third molar surgery, pre-emptive etoricoxib reduced postoperative pain, while montelukast decreased inflammation and modulated tumor necrosis factor-alpha levels. The results of the study do not support the use of the alternative pre-emptive analgesic regimens."

Clinical • Clinical data • Journal • Infectious Disease • Oncology • Pain • TNFA

Multimodal evaluation of lipoxygenase-targeting NSAIDs using integrated in vitro, SAR, in silico, cytotoxicity towards MCF-7 cell line, DNA docking and MD simulation approaches. (PubMed, Int J Biol Macromol) - "We reported earlier that several NSAIDs, including naproxen, aspirin and acetaminophen, inhibited lipoxygenase (LOX) enzyme at sub-micromolar concentrations...Aceclofenac (IC50 0.85 ± 0.06 μM) was the most active drug, followed by indomethacin (IC50 1.13 ± 0.07 μM), meloxicam (IC50 1.94 ± 0.07 μM) and ketorolac (IC50 9.26 ± 0.82 μM). Celecoxib (IC50 15.81 ± 0.71 μM), lornoxicam (IC50 16.54 ± 0.28 μM) and nimesulide (IC50 19.87 ± 0.85 μM) showed excellent inhibitory profiles. Flurbiprofen (IC50 21.73 ± 0.93 μM) and etoricoxib (IC50 24.93 ± 0.64 μM) moderately inhibited the target enzyme...Density functional theory (DFT) and ESP studies, MD simulations and MMPBSA free energy calculations further reiterated the stability of ligand-receptor complexes. Overall, these findings highlight the potential of targeted NSAIDs as dual COX/LOX inhibitors with broader therapeutic relevance in inflammatory disorders."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor

PTGS2 Silencing Inhibits Ferroptosis in Staphylococcus Aureus-induced Osteomyelitis By Blocking the IL-17A Signaling Pathway. (PubMed, Inflammation) - "Silencing PTGS2 reduces ferroptosis in S. aureus-induced osteomyelitis by obstructing the IL-17A pathway, which suggests a new approach for the treatment of osteomyelitis."

Journal • Infectious Disease • Inflammation • Orthopedics • GPX4 • IL17A • IL1B • IL6 • NOS2 • PACERR • PTGS2 • SLC7A11 • SOCS3 • TIMP1 • TNFA

Intra-articular treatment of osteoarthritis using novel biocompatible etoricoxib chitosan-hyaluronate hybrid microparticles. (PubMed, J Microencapsul) - "In vivo studies demonstrated that ME4/TPP0.25 significantly suppressed knee joint swelling, and significantly reduced the levels of catabolic and inflammatory mediators (ALP and IL-6) compared to drug alone. These results suggest that the optimum ETX-loaded PEMPs could be a promising formulation for knee osteoarthritis management."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology • IL6

Fixed drug eruption induced by Etoricoxib in Thailand: A case report. (PubMed, Toxicol Rep) - "The patient was treated with oral Prednisolone, antihistamines, and topical steroids, resulting in significant clinical improvement within 12 days. This case highlights the potential of Etoricoxib to trigger generalized bullous fixed drug eruption (GBFDE), which is a more severe variant involving more than three body sites and classified as one of the Severe Cutaneous Adverse Reactions (SCARs), emphasizing the need for prompt recognition and appropriate management to prevent recurrence and mitigate symptoms."

Journal • Dermatology • Pruritus

Primary Hypertrophic Osteoarthropathy-A Rare Cause of Joint Pain. (PubMed, J Assoc Physicians India) - "The patient was given an infusion of 4 mg of zoledronic acid, along with etoricoxib, once daily. The patient responded to treatment with significant reduction in pain at 4 weeks and etoricoxib was stopped."

Journal • Back Pain • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain

Impact of Ginkgo biloba drug interactions on bleeding risk and coagulation profiles: A comprehensive analysis. (PubMed, PLoS One) - "However, interactions with anticoagulants including direct oral anticoagulants and acenocoumarol, were not statistically significant in our analysis...Specific medications, including clopidogrel, aspirin, celecoxib, loxoprofen, nifedipine, and omeprazole, were significantly associated with the risk of bleeding and abnormal coagulation (p <  0.05). Interactions with ticagrelor, etoricoxib, insulin, omeprazole, and domperidone were associated with abnormal coagulation tests without affecting the reported bleeding. These findings underscore the critical need of evaluating potential interactions involving Ginkgo biloba extract drug interactions in clinical pratice, particularly when assessing bleeding risk and managing coagulation."

Journal • Observational data • Retrospective data • Hematological Disorders

Development of Etoricoxib loaded mesoporous silica nanoparticles laden gel as vehicle for transdermal delivery: Optimization, ex-vivo permeation, histopathology and in-vivo anti-inflammatory study. (PubMed, Drug Dev Ind Pharm) - "The histopathological examination confirmed that optimized ETB-MSNPs gel did not exhibit any toxicity on the skin. Based on the findings, the results suggest that the MSNPs gel has the potential as a carrier for enhancing the therapeutic efficacy of ETB through topical delivery, although further studies are needed to fully confirm its effectiveness."

Journal • Preclinical • Gastrointestinal Disorder • IL1B • TNFA

The improvement of rimaprost in residual symptoms in patients after spinal decompression for spinal cervical spondylosis: a prospective randomised controlled study (ChiCTR) - P4 | N=72 | Completed | Sponsor: Qilu Hospital of Shandong University; Qilu Hospital of Shandong University

New P4 trial

Simultaneous determination of lesinurad and co-administered drugs used in management of gout comorbidities to uncover potential pharmacokinetic interaction in rat plasma. (PubMed, Sci Rep) - "This work presents a novel, simple, and sensitive high performance liquid chromatography (HPLC) method for the simultaneous determination of lesinurad (LES) and other co-administered drugs that are subject to potential pharmacokinetic interactions such as etoricoxib (ETC), eplerenone (EPL), and amiodarone (AMD) in rat plasma. This raises concerns of the possible renal injurious effect of ETC when co-prescribed with LES. Moreover, this work uncovers the necessity for therapeutic dose adjustment or increased clinical vigilance for side effects and/or lack of efficacy upon concomitant administration of the selected drugs to gout patients."

Journal • PK/PD data • Preclinical • Gout • Immunology • Inflammatory Arthritis • Rheumatology

Inhibition of COX2 impairs angiogenesis and causes vascular defects in developing zebrafish embryos. (PubMed, Int J Dev Biol) - "This study investigated the role of cyclooxygenase-2 (COX2) in angiogenesis during zebrafish embryogenesis by inhibiting COX2 activity with etoricoxib...Additionally, reduced expression of ephrinb and prox1 affected arterial and venous identity formation. These results demonstrate that COX2 is essential for proper angiogenesis during zebrafish development, and its inhibition leads to significant vascular defects, underscoring COX2's crucial role in regulating VEGFA-mediated angiogenesis."

Journal • Cardiovascular • KDR

Celecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis. (PubMed, BMB Rep) - "Celecoxib significantly inhibited clinical arthritis and bone progression in the joints of SKGc, but not etoricoxib (another COX-2i), nor naproxen (COX-2 nonselective). Of the NSAIDs, only celecoxib inhibited bone progression in SKGc and OB differentiation and bone mineralization in the BdCs of mice and AS patients via CDH11/WNT signaling, independent of the COX-2 inhibition. [BMB Reports 2025; 58(3): 140-145]."

Biomarker • Clinical • Clinical guideline • Journal • Observational data • Retrospective data • Review • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Oncology • Osteoarthritis • Osteosarcoma • Rheumatology • Sarcoma • Seronegative Spondyloarthropathies • Solid Tumor • Spondylarthritis • CDH11

An Up-to-Date Description of the Use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Italy: Evidence from Real Clinical Practice. (PubMed, Adv Ther) - "The analysis showed that patients prescribed with NSAIDs were relatively young (~ 60 years), in contrast with the pathologies covered by Note 66, which typically affect elderly people. Moreover, rheumatic and oncological diseases were poorly represented, thus it is possible that NSAIDs might have been prescribed for indications outside the note. These findings suggest that the use of NSAIDs for pain management in Italy should be optimized, properly weighting their risks and benefits."

Journal • Gout • Immunology • Musculoskeletal Pain • Oncology • Osteoarthritis • Pain • Rheumatology

Formulation and Characterization of Etoricoxib Suppositories for the Management of Hemorrhoids. (PubMed, Turk J Pharm Sci) - "The SB3 gave 91.47±17.74% drug release in 6 h, whereas the SB1 gave 99.08±3.40% drug release in 12 h. Drug release from all formulations of suppositories was supported by zero-order, first-order, and Higuchi plots, except for SB4. The SB2 results were found to be more appropriate than those of the other batches. These results confirm that the prepared formulation has a future scope and should be further explored in in vitro cell lines and animal studies."

Journal • Gastroenterology • Gastrointestinal Disorder

Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis (clinicaltrials.gov) - P3 | N=72 | Recruiting | Sponsor: Laboratorios Silanes S.A. de C.V.

New P3 trial • Gout • Immunology • Inflammatory Arthritis • Rheumatology